Better glycaemic control with once-weekly insulin icodec versus once-daily insulin degludec in adults with insulin-naïve type 2 diabetes (ONWARDS 3)
In this medfyle
Once-weekly icodec showed superior HbA1c reduction vs. once-daily degludec after 26 weeks, with no difference in weight change and a higher rate of combined level 2 or 3 hypoglycaemic events.
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.